{"id":"antihistamine-cetirizine-hydrochloride","safety":{"commonSideEffects":[{"rate":"6-9%","effect":"Somnolence"},{"rate":"7-12%","effect":"Headache"},{"rate":"4-6%","effect":"Fatigue"},{"rate":"3-5%","effect":"Dry mouth"},{"rate":"2-4%","effect":"Pharyngitis"}]},"_chembl":null,"_dailymed":{"setId":"16423890-f64a-1b02-e063-6294a90a403e","title":"ALLEXPERT 24HR ANTIHISTAMINE CETIRIZINE HYDROCHLORIDE ORAL SOLUTION (ALLEXPERT 24HR ANTIHISTAMINE CETIRIZINE HYDROCHLORIDE) SOLUTION [BOWONG TECHNOLOGY (SHENZHEN) CO.,LTD]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Cetirizine is a selective H1-receptor antagonist that crosses the blood-brain barrier minimally, reducing central nervous system effects compared to first-generation antihistamines. By competitively blocking histamine binding to H1 receptors on mast cells, basophils, and other immune cells, it suppresses the release and effects of histamine, thereby alleviating allergic symptoms such as itching, urticaria, and rhinitis.","oneSentence":"Cetirizine hydrochloride blocks histamine H1 receptors on cells, preventing histamine-mediated allergic responses.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T04:53:15.003Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Allergic rhinitis (seasonal and perennial)"},{"name":"Chronic urticaria"},{"name":"Allergic conjunctivitis"},{"name":"Allergic asthma"}]},"trialDetails":[{"nctId":"NCT05660083","phase":"PHASE2","title":"Alpelisib/iNOS Inhibitor/Nab-paclitaxel in Patients With HER2 Negative Metaplastic Breast Cancer (MpBC)","status":"RECRUITING","sponsor":"The Methodist Hospital Research Institute","startDate":"2023-01-12","conditions":"HER2-negative Breast Cancer, Metastatic Breast Cancer, Metaplastic Breast Carcinoma","enrollment":36},{"nctId":"NCT02604199","phase":"PHASE2","title":"A Multi-dose Study of ARC-520 in Patients With Hepatitis B 'e' Antigen (HBeAg) Negative, Chronic Hepatitis B Virus (HBV) Infection","status":"TERMINATED","sponsor":"Arrowhead Pharmaceuticals","startDate":"2015-09","conditions":"Hepatitis B","enrollment":58},{"nctId":"NCT02738008","phase":"PHASE2","title":"Extension Study of the Safety and Efficacy of Multi-dose Intravenous ARC-520 in Patients With Chronic Hepatitis B (HBV) Infection","status":"TERMINATED","sponsor":"Arrowhead Pharmaceuticals","startDate":"2016-03","conditions":"Hepatitis B","enrollment":12},{"nctId":"NCT02577029","phase":"PHASE2","title":"Study of ARC-520 With or Without Other Drugs Used in the Treatment of Chronic Chronic Hepatitis B Virus (HBV)","status":"TERMINATED","sponsor":"Arrowhead Pharmaceuticals","startDate":"2015-12","conditions":"Hepatitis B, Hepatitis D","enrollment":79},{"nctId":"NCT02604212","phase":"PHASE2","title":"A Multi-dose Study of ARC-520 in Patients With Hepatitis B 'e' Antigen (HBeAg) Positive, Chronic Hepatitis B Virus Infection","status":"TERMINATED","sponsor":"Arrowhead Pharmaceuticals","startDate":"2015-11","conditions":"Hepatitis B","enrollment":32},{"nctId":"NCT07236372","phase":"NA","title":"Comparing Standard-Dose and High-Dose Cetirizine for Acute Urticaria","status":"NOT_YET_RECRUITING","sponsor":"University of Phayao","startDate":"2025-11","conditions":"Acute Urticaria","enrollment":140},{"nctId":"NCT04568902","phase":"PHASE1","title":"Study of H3B-6545 in Japanese Women With Estrogen Receptor (ER)-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer","status":"COMPLETED","sponsor":"Eisai Co., Ltd.","startDate":"2020-09-30","conditions":"Breast Neoplasms","enrollment":33},{"nctId":"NCT06754410","phase":"PHASE3","title":"Efficacy of Antihistamine Drugs as Medical Expulsive Therapy Alone or in Combination With Alpha Blockers: A Prospective Randomized Controlled Study","status":"COMPLETED","sponsor":"South Valley University","startDate":"2021-03-01","conditions":"Lower Ureteric Stones","enrollment":480},{"nctId":"NCT03167216","phase":"EARLY_PHASE1","title":"Mast Cells in Male Pelvic Pain and and Lower Urinary Tract Dysfunction","status":"COMPLETED","sponsor":"Northwestern University","startDate":"2017-08-01","conditions":"Chronic Prostatitis With Chronic Pelvic Pain Syndrome","enrollment":20},{"nctId":"NCT06118710","phase":"PHASE4","title":"Evaluation of the Omission of Dexamethasone in Premedication Regimens During Paclitaxel Treatment","status":"RECRUITING","sponsor":"Erasmus Medical Center","startDate":"2024-06-25","conditions":"Cancer","enrollment":500},{"nctId":"NCT06535087","phase":"","title":"The Impact of Airway Allergic Diseases on Children's and Parents' Quality of Life","status":"RECRUITING","sponsor":"Wenjing Zhou","startDate":"2024-07-20","conditions":"Pediatric Asthma, Rhinitis, Allergic, Quality of Life","enrollment":600},{"nctId":"NCT04990388","phase":"PHASE1, PHASE2","title":"Safety, Tolerability, and Pharmacokinetics of UX053 in Patients With Glycogen Storage Disease Type III (GSD III)","status":"TERMINATED","sponsor":"Ultragenyx Pharmaceutical Inc","startDate":"2021-10-18","conditions":"Glycogen Storage Disease Type III","enrollment":9},{"nctId":"NCT06126991","phase":"PHASE1, PHASE2","title":"Organ Protective Effect of Cetirizine In Patients With Severe Burns","status":"UNKNOWN","sponsor":"Ruijin Hospital","startDate":"2024-01-23","conditions":"Burns","enrollment":32},{"nctId":"NCT05275933","phase":"PHASE2, PHASE3","title":"Efficacy of TCM Capsules Lian Hua Qing Wen Jiao Nang in Mild COVID-19 Patients","status":"COMPLETED","sponsor":"Singapore Chung Hwa Medical Institution","startDate":"2022-04-05","conditions":"COVID-19","enrollment":93},{"nctId":"NCT05803070","phase":"","title":"Topical Cetirizine in Treatment of Localized Alopecia Areata","status":"UNKNOWN","sponsor":"Assiut University","startDate":"2023-09-01","conditions":"Alopecia Areata","enrollment":59},{"nctId":"NCT00794794","phase":"PHASE3","title":"Taste Test Between Desloratadine and Cetirizine Syrup in Children (Study P03826)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2004-11","conditions":"Allergic Rhinitis","enrollment":204},{"nctId":"NCT00794378","phase":"PHASE3","title":"Taste Test Between Desloratadine and Cetirizine Syrup in Children (Study P03829)(COMPLETED)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2004-11","conditions":"Allergic Rhinitis","enrollment":202},{"nctId":"NCT04706559","phase":"NA","title":"Efficacy of Oral Supplementation of Probiotics in Children With Atopic Dermatitis","status":"COMPLETED","sponsor":"B.P. Koirala Institute of Health Sciences","startDate":"2021-01-03","conditions":"Atopic Dermatitis","enrollment":98},{"nctId":"NCT04179461","phase":"PHASE2","title":"Personalized Treatment Algorithms for Difficult-to-treat Asthma","status":"COMPLETED","sponsor":"Children's Hospital Medical Center, Cincinnati","startDate":"2018-03-16","conditions":"Asthma in Children","enrollment":21},{"nctId":"NCT04935515","phase":"NA","title":"C Reactive Protein in Home Quarantined Coronavirus Disease 2019 (COVID -19) Patients.","status":"COMPLETED","sponsor":"Manimarane Arjunan, MD,DM (Cardiology)","startDate":"2021-04-15","conditions":"COVID -19","enrollment":25},{"nctId":"NCT02583594","phase":"PHASE1","title":"A Study to Characterize Subcutaneous or Intravenous Alemtuzumab in Patients With Progressive Multiple Sclerosis","status":"COMPLETED","sponsor":"Genzyme, a Sanofi Company","startDate":"2015-12-06","conditions":"Progressive Multiple Sclerosis","enrollment":24},{"nctId":"NCT04612803","phase":"","title":"Prevalence of Antihistamine Responsive Irritable Bowel Syndrome With Diarrhea","status":"UNKNOWN","sponsor":"University of Cincinnati","startDate":"2020-11-15","conditions":"Irritable Bowel Syndrome, Dermatographism, Post-prandial Diarrhea","enrollment":100},{"nctId":"NCT03192488","phase":"PHASE4","title":"Effect of an H1 Receptor Antagonist on Exercise Performance in Hypoxia","status":"COMPLETED","sponsor":"Indiana University","startDate":"2017-08-31","conditions":"Hypoxia, Altitude","enrollment":13},{"nctId":"NCT02665754","phase":"PHASE1","title":"Intralymphatic Immunotherapy for House Dust Mite, Dog, and Cat Allergy Using Tyrosine S® in Allergic Rhinitis","status":"COMPLETED","sponsor":"Gachon University Gil Medical Center","startDate":"2016-07","conditions":"Allergic Rhinitis","enrollment":32},{"nctId":"NCT03296358","phase":"NA","title":"Adding a Short Burst of Corticosteroid to the Conventional Treatment of H1 Antihistamines in Emergency Department.","status":"COMPLETED","sponsor":"Chulalongkorn University","startDate":"2017-10-01","conditions":"Urticaria, Allergy","enrollment":75},{"nctId":"NCT01825655","phase":"PHASE4","title":"Study of Using Long Acting Antihistamine to Treat Opioid Induced Itching","status":"TERMINATED","sponsor":"Virginia Commonwealth University","startDate":"2014-09","conditions":"Pruritus","enrollment":3},{"nctId":"NCT00490204","phase":"PHASE3","title":"Cetirizine Placebo Controlled Study For Perennial Allergic Rhinitis","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-07-27","conditions":"Rhinitis, Allergic, Perennial","enrollment":239},{"nctId":"NCT00866788","phase":"PHASE2","title":"A Study of Xolair (Omalizumab) in Patients With Chronic Idiopathic Urticaria (CIU) Who Remain Symptomatic With Antihistamine Treatment (H1)","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2009-03","conditions":"Chronic Idiopathic Urticaria","enrollment":90},{"nctId":"NCT02613910","phase":"PHASE3","title":"Long-Term Extension Study of Ofatumumab in Subjects With Pemphigus Vulgaris","status":"TERMINATED","sponsor":"GlaxoSmithKline","startDate":"2015-12-23","conditions":"Pemphigus","enrollment":1},{"nctId":"NCT02451579","phase":"NA","title":"A Clinical Trial Evaluating the Role of Systemic Antihistamine Therapy in the Reduction of Adverse Effects Associated With Topical 5-aminolevulinic Acid Photodynamic Therapy","status":"COMPLETED","sponsor":"Goldman, Butterwick, Fitzpatrick and Groff","startDate":"2015-02","conditions":"Actinic Keratoses","enrollment":20},{"nctId":"NCT01985789","phase":"PHASE4","title":"Anti-histamines and Methacholine Challenges.","status":"COMPLETED","sponsor":"Don Cockcroft","startDate":"2013-11","conditions":"Asthma","enrollment":12},{"nctId":"NCT01940393","phase":"PHASE4","title":"Evaluation of the Inhibitory Effect of 5 Anti-Histamines in Urticaria","status":"COMPLETED","sponsor":"Grupo de Alergología Clínica y Experimental","startDate":"2013-08","conditions":"Urticaria","enrollment":150},{"nctId":"NCT01781507","phase":"PHASE4","title":"Study of Bronchodilation Effects of Cetirizine","status":"COMPLETED","sponsor":"California Allergy and Asthma Medical Group, Inc.","startDate":"2011-06","conditions":"Allergic Rhinitis, Asthma","enrollment":21},{"nctId":"NCT00561717","phase":"PHASE4","title":"A Randomized, Placebo Controlled Study to Determine the Efficacy and Speed of a Nasal Spray in Allergen Induced Seasonal Allergic Rhinitis","status":"COMPLETED","sponsor":"Bayer","startDate":"2007-10","conditions":"Seasonal Allergic Rhinitis","enrollment":70},{"nctId":"NCT00610584","phase":"NA","title":"Acupuncture for Seasonal Allergic Rhinitis","status":"COMPLETED","sponsor":"Charite University, Berlin, Germany","startDate":"2008-04","conditions":"Seasonal Allergic Rhinitis","enrollment":422},{"nctId":"NCT01127620","phase":"PHASE3","title":"Efficacy Study for the Symptomatic Treatment of Perennial Allergic Rhinitis With a 1 Year Safety Extension","status":"COMPLETED","sponsor":"Faes Farma, S.A.","startDate":"2004-05","conditions":"Perennial Allergic Rhinitis","enrollment":650},{"nctId":"NCT00240032","phase":"PHASE4","title":"A Study to Evaluate the Impact on Skin (Injection Site) Reactions of Taking an Antihistamine (Zyrtec®) or Placebo Prior to Daily Injections of Copaxone®.","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2004-10","conditions":"Multiple Sclerosis","enrollment":80},{"nctId":"NCT00533637","phase":"PHASE2","title":"Taste and Local Tolerance Study of NLA Nasal Spray in Patients With Allergic Rhinitis","status":"COMPLETED","sponsor":"Biolipox AB","startDate":"2007-09","conditions":"Allergic Rhinitis","enrollment":28}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":62,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Antihistamine Cetirizine Hydrochloride","genericName":"Antihistamine Cetirizine Hydrochloride","companyName":"Goldman, Butterwick, Fitzpatrick and Groff","companyId":"goldman-butterwick-fitzpatrick-and-groff","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Cetirizine hydrochloride blocks histamine H1 receptors on cells, preventing histamine-mediated allergic responses. Used for Allergic rhinitis (seasonal and perennial), Chronic urticaria, Allergic conjunctivitis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}